Avis Budget Group, Inc. CAR
123.71 USD +2.02 (+1.66%)
Regular-session close
123.71 0.00 0.00%
After hours · Nov 19, 5:15 PM ET
118.31 Day range 124.64
85.96 52-week range 847.70
- YTD
- -3.60%
- 1 year
- -6.42%
News
globenewswire.com Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate -Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates
businesswire.com HSS Study Highlights Potential for CAR T-Cell Therapy to Transform Lupus Treatment ORLANDO, Fla.--(BUSINESS WIRE)--A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a…
seekingalpha.com Avis: A More Balanced Outlook After The Short Squeeze (Upgrade) Avis Budget Group experienced a dramatic short squeeze, surging from $100 to $800 before collapsing as institutional holders exited. Pentwater Capital's exit and subsequent $650 million settlement…
zacks.com Avis Budget Stock Appreciates 10% Despite Earnings Miss in Q3 CAR shares jump 10.2% despite a Q3 earnings miss, as record fleet utilization, improved cash flow and expectations of Q4 EBITDA recovery draw attention.
marketbeat.com Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have…benzinga.com JP Morgan Maintains Underweight on Avis Budget Gr, Lowers Price Target to $85 JP Morgan analyst Rajat Gupta maintains Avis Budget Gr (NASDAQ:CAR) with a Underweight and lowers the price target from $105 to $85.
benzinga.com Goldman Sachs Maintains Sell on Avis Budget Gr, Raises Price Target to $108 Goldman Sachs analyst Salveen Richter maintains Avis Budget Gr (NASDAQ:CAR) with a Sell and raises the price target from $94 to $108.
benzinga.com Susquehanna Maintains Neutral on Avis Budget Gr, Lowers Price Target to $125 Susquehanna analyst Christopher Stathoulopoulos maintains Avis Budget Gr (NASDAQ:CAR) with a Neutral and lowers the price target from $140 to $125.
seekingalpha.com Avis Budget Group, Inc. (CAR) Q3 2026 Earnings Call Transcript Avis Budget Group, Inc. ( CAR ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants David Calabria - Treasurer & Senior VP of Corporate Finance Brian Choi - Chief Executive…
marketbeat.com What Avis Budget Group (CAR) Said on Its Q3 Earnings Call Avis Budget Group NASDAQ: CAR reported third-quarter adjusted EBITDA of $513 million, down 8% from a year earlier and about $50 million below the company's prior expectations, as weaker travel demand…
benzinga.com Avis Budget Gr Q3 2026 Earnings Call Transcript Avis Budget Gr (NASDAQ:CAR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
prnewswire.com Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa…
zacks.com Compared to Estimates, Avis Budget (CAR) Q3 Earnings: A Look at Key Metrics The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
zacks.com Avis Budget Group (CAR) Misses Q3 Earnings Estimates Avis Budget Group (CAR) came out with quarterly earnings of $5.15 per share, missing the Zacks Consensus Estimate of $8.47 per share. This compares to earnings of $10.11 per share a year ago.
benzinga.com 12 Industrials Stocks Moving In Tuesday's After-Market Session Gainers iPower (NASDAQ:IPW) stock increased by 15.8% to $1.9 during Tuesday's after-market session. Richtech Robotics (NASDAQ:RR) shares rose 3.05% to $0.96. The market value of their outstanding…
globenewswire.com Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…
defenseworld.net Avis Budget Group, Inc. $CAR Stock Sold by Hennessy Advisors Inc. Hennessy Advisors Inc. decreased its stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) by 8.9% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The…benzinga.com Barclays Maintains Equal-Weight on Avis Budget Gr, Lowers Price Target to $115 Barclays analyst Dan Levy maintains Avis Budget Gr (NASDAQ:CAR) with a Equal-Weight and lowers the price target from $160 to $115.
benzinga.com 10 Industrials Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
seekingalpha.com Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in…
zacks.com Earnings Preview: Avis Budget Group (CAR) Q3 Earnings Expected to Decline Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com Avis First Expands to London Heathrow and Paris Charles de Gaulle Airports PARSIPPANY, N.J.--(BUSINESS WIRE)--Avis announced the expansion of Avis First to London Heathrow and Paris Charles de Gaulle airports, bringing its premium car rental service to more than 30 airport…
prnewswire.com Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities…
gurufocus.com TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an inves
gurufocus.com Avis Budget Group Inc (CAR) Shares Fall 4.0% -- What GF Score of 72 Tells Investors On October 21, 2026, Avis Budget Group Inc (CAR) shares fell 4.0%, bringing the current price to $98.39. This price is down significantly from its 52-week high
zacks.com New Strong Sell Stocks for October 20th CAR, USAS and APC have been added to the Zacks Rank #5 (Strong Sell) List on October 20, 2026.
accessnewswire.com Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center…
